{
    "title": "Medical Attributes of Sanguinaria canadensis - Bloodroot",
    "inventor_name": "Abigail Redmond",
    "publication_year": 2003,
    "device_name": "Cansema (Bloodroot salve)",
    "goal": "To treat skin cancer and other skin disorders using a topical bloodroot extract.",
    "problem_addressed": "Skin cancer (basal cell carcinoma, cervical cancer cells), oral leukitis, periodontal disease, and certain bacterial infections.",
    "concept_summary": "Bloodroot (Sanguinaria canadensis) rhizome extracts contain the alkaloid sanguinarine and related benzophenanthridine compounds. These compounds exhibit antimicrobial, anti-inflammatory, and cytotoxic activities. The Cansema system is a topical salve that applies the extract to skin lesions, purportedly discriminating between healthy and cancerous tissue while also serving as a diagnostic aid.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Antimicrobial activity",
        "Cytotoxicity against tumor cells",
        "NF-kappaB pathway inhibition",
        "Induction of apoptosis"
    ],
    "scientific_domains": [
        "Botany",
        "Pharmacology",
        "Oncology",
        "Microbiology"
    ],
    "mechanisms_of_action": [
        "Inhibition of NF-kappaB activation",
        "Disruption of bacterial cell membranes",
        "Induction of oxidative stress in neutrophils",
        "Apoptosis via glutathione depletion"
    ],
    "materials": [
        "Sanguinarine",
        "Benzophenanthridine alkaloids",
        "Bloodroot rhizome",
        "Methanol (extraction solvent)"
    ],
    "energy_sources": [],
    "inputs": [
        "Harvested bloodroot plant material",
        "Extraction solvent (e.g., methanol)",
        "Formulation ingredients for salve"
    ],
    "outputs": [
        "Topical salve (Cansema)",
        "Oral rinse (Viadent)",
        "Extract powder"
    ],
    "claimed_performance": "In vitro MIC values of 12.5-62.5 ug/ml against bacteria; tumor cell death observed at 2.12-4.24 uM sanguinarine; clinical studies show mixed results for periodontitis and oral leukoplakia.",
    "experimental_evidence": "Multiple in-vitro studies (e.g., MIC, cytotoxicity assays) and limited clinical trials (double-blind studies on periodontitis, case-control study on oral leukoplakia).",
    "replication_status": "No explicit replication reported; claims are based on literature citations.",
    "keywords": [
        "Bloodroot",
        "Sanguinaria canadensis",
        "Sanguinarine",
        "Skin cancer",
        "Topical salve",
        "Cansema",
        "Antimicrobial",
        "Apoptosis"
    ],
    "related_technologies": [
        "Viadent mouthrinse",
        "Black Salve (AO Black Salve)",
        "Chlorhexidine oral rinse"
    ],
    "controversy_level": "high",
    "confidence_score": 0.78,
    "practicability_score": 0.62,
    "fringe_score": 0.71,
    "evidence_strength": 0.52,
    "risk_score": 0.64,
    "trl_estimate": 3,
    "source_urls": [
        "http://www.klemow.wilkes.edu/Sanguinaria.html",
        "http://www.meditopia.org",
        "http://www.altcancer.com/"
    ],
    "organizations": [
        "Alpha Omega Labs",
        "Herbologics S.A.",
        "Wilkes University (BIO 368 - Medical Botany course)"
    ],
    "applications": [
        "Topical treatment of basal cell carcinoma",
        "Adjunct therapy for periodontitis",
        "Antimicrobial agent for gastrointestinal infections"
    ],
    "limitations": [
        "Lack of robust clinical trial data",
        "Non-specific cytotoxicity (affects normal cells)",
        "Potential for scarring and residual tumor",
        "Regulatory warnings and FDA opposition"
    ],
    "open_questions": [
        "Efficacy of Cansema in controlled in-vivo cancer models",
        "Optimal dosing and formulation to maximize tumor selectivity",
        "Long-term safety profile for repeated topical use"
    ],
    "red_flags": [
        "Claims of \"miraculous\" cure and discrimination between healthy and cancerous tissue",
        "Marketing as a diagnostic tool without regulatory approval",
        "Historical FDA legal actions against related products"
    ],
    "evidence_quotes": [
        "Sanguinarine extracts are not lytic to neutrophils but even at very low concentrations (0.001%) will inhibit neutrophil chemotaxis, oxidative metabolism and degranulation within 5 minutes (Agarwal et al 1997).",
        "Uterine cervical cancer treatment with 2.12 or 4.24 uM sanguinarine induced cell death in most pathogenic cells (Ding et al 2002).",
        "S. canadensis was found to have significant antimycobacterial activity against M. aurum only (MIC=62.5 ug/ml) (Newton et al 2001).",
        "A 14-week controlled clinical trial supported the combined use of chlorhexidine mouthrinse followed by sanguinaria mouthrinse and toothpaste up to three months in treating periodontitis (Tenenbaum et al 1999).",
        "Four cases in which patients had used sanguinarine extracts in lieu of the recommended conventional treatment for basal cell carcinomas showed scarring and residual tumor (McDaniel and Goldman 2002)."
    ]
}